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INTERNATIONAL SAFETY REGULATIONS
ON LIVING MODIFIED ORGANISMS :
TRADE、 AND NON-TRADE INTERESTS
IN HARMONY OR CONFLICT?
BIRHANU Fikremarkos *
Abstract
D冒spite the fact that biotechnology has already become a key technology of the
21st century, the global debate over its benefits and risks remains unsettled. On
the one hand, there appears to be a general consensus on the potential benefit of
biotechnology m general and genetic engineering in particular. On the other hand,
concerns are still abound on its potential impacts on human health and the
environment. With such a scenario, states have no option but to regulate the
safety of the technology both at the national and international level with a view
to minimize the potential risks. The increasing trend of the commercialization of
genetically engineered organisms and their consequent potential for transboudary
movement have made the issue of safety no longer a national agenda and have
given impetus to states to look for a multilateral setting on safety issues. The
Cartagena Protocol is the first and the only international agreement governing the
transboundary movement of genetically engineered organisms. The Protocol lays
down different conditions and procedures on the transboundary movement of
genetically engineered organisms. The Protocol, being basically an environmental
agreement, its relation to and impact on international trade has remained unclear
and at times controversial.
Keywords : Biosafety, Cartagena Biosafety Protocol, Convention on Biological
Diversity, living modified organism, precautionary principle, risk
assessment.
*Doctoral Candidate, School of International Public Policy (OSIPP), Osaka University.
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As the global debate on the introduction of living modified organisms (LMOs)
continues unabated, sates are increasingly becoming concerned with the potential
risks of such organisms on human health and the environment. The concern has
further been exacerbated by the increasing trend in the commercialization of
LMOs. As a result, the need for regulation of LMOs has recently become high
in the agenda of states. A number of countries have already put in place the
necessary regulatory framework on LMOs while others are in the process of doing
l′ノ
SO.
With the expansion of LMOs growing and commercialization, the possibility of
their transboundary movement is also increasing and regulation of LMOs is no
longer only a national agenda. The aggressive commercialization of LMOs has
made it difficult to deal with their safety solely on national regulatory regimes
and has necessitated the need for an international biosafety regime.
The Cartagena Protocol on Biosafety (the Cartagena Protocol or the Protocol)
was negotiated and adopted to serve as an international regulatory regime on the
transboundary movement of LMOs. The Protocol is the only international
agreement that specifically deals with cross-boundary transactions involving
LMOs. The Protocol being an agreement with an immense implication on
international trade involving LMOs, its relation with and impact on the
agreements of the World Trade Organization (WTO remains controversial.
This article attempts to evaluate the relationship between the Protocol and the
relevant WTO Agreements and determine whether the agreements are in conflict
1) Different terminologies are used to refer to the organisms such as, genetically modified organisms
(GMOs), or genetically engineered organisms (GEOs). While GMO is the most frequently used term, the
Cartagena Biosafety Protocol (discussed below at section 2) employs the term LMO. This later term is
used m this paper. Even if the drafting history of the Cartagena Biosafety Protocol shows that the term
living modified organism was used because of lack of consensus to use the term. GMO, the practical
difference among the terminologies does not seem to be clear. See in general, A Gupta, "Creating a
Global Biosafety Regime" 2 International Journal of Biotechnology (2000).
2 ) In 2002 GM crops covered 58 million hectares worldwide and several countries are now commercially
growing GM crops. By producing 105 acres in 2003-which is about two-third of the total world LMO
production-the US remains by far the largest producer of LMOs. Argentina, which produces 85 per cent
of all the LMO produced by developing countries in 2003 stands as the second largest producer followed
by Canada. For details, see James, C. "status of commercialized transgenic crops: 2002" ISAAA Briefs No.
27, and Genetically Modified Crops in the United States", Pew Initiative on Food and Biotechnology
(2004), available at http://www.pewagbiotech.org/resources/factsheet.htm.
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or harmony. In doing so, the article will first present a general background to the
Protocol and analyze its relationship with the different WTO agreements which
are thought to be related with the issue of LMOs. That will be followed by a
determination of whether there is a conflict between the two regimes and analysis
of different approaches to resolve potential conflicts under different scenarios.
2. The Cartagena Protocol on Biosafety
The parent international instrument for the Cartagena Biosafety Protocol is the
Convention on Biological Diversity (CBD) which came to force in 1992. As the
name implies, the CBD is concerned with biodiversity. The CBD has three main
objectives: the conservation of biodiversity, the sustainable use of its components
and the fair and equitable sharing of benefits arising from the utilization of
genetic resources. Articles 16 and 19 recognize the positive role of biotechnology
m the fulfillment of the objectives of the CBD, and in particular, Article 16 states
that access to and transfer of biotechnology is essential elements for the
attainment of the objective of the CBD. Three provisions of the CBD have direct
relevance to LMOs. First, Article 19(3) envisages the need for a protocol on
biosafety for LMOs. Second, Article　8(g), which deals with national measures,
obliges parties to the CBD to regulate, manage and control the risk associated
with LMOs resulting from biotechnology which are likely to have impacts on the
conservation and sustainable use of biodiversity. The third Article, Article 19(4),
requires each member to share information on domestic regulations concerning use
and safety of LMOs with any other member.
2.1 Background to the drafting process of the Cartageれa Protocol
The Second Conference of the Parties to the CBD , which was held in 1995,
agreed on the need for a biosafety protocol as envisaged under Article 19 (3) of the
Convention and to that end designated an Ad-Hoc Working Group to draft and
3) Article 1 of the CBD.
4) According to Article 23, the Conference of the Parties to the CBD is the highest decision making body
which meets at regular intervals determined by the Conference itself to review different issues specifically
entrusted to it under Article 23.
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negotiate the protocol. The Protocol was then drafted and tabled for negotiation,
but the task did not turn out to be easy and negotiating parties were not able to
come to consensus on several issues. The Protocol was expected to be adopted
during the 1999 Extraordinary Meeting of the Conference of the Parties to the
CBD, held m Cartagena, Columbia, but the deep division among members on
several issues remained unresolved and the adoption of the protocol had to wait
for almost a year when a compromised agreement was reached and the Protocol
was adopted on January 29, 2000 in Montreal, Canada, by representatives of 133
countries. The most important issues of friction among the different groups
during the negotiation were the scope of the Protocol, the relationship between the
Protocol and other international agreements (especially WTO) and issues related to
liability and redress in cases where LMOs cause damage. While parties reached
a compromised solution on the first two issues albeit with a lot of ambiguity and
confusion, the third issue was left for the Conference of the Parties to ''adopt a
process with respect to the appropriate elaboration of international rules and
procedures m the field of liability and redress for damage resulting from
transboundary movement of living modified organisms..."8
/
The objective of the protocol is stated as follows:
In accordance with the precautionary approach contained in Principle
15　0f the Rio Declaration on Environment and Development, the
objective of this Protocol is to contribute to ensuring an adequate level
of protection in the field of the safe transfer, handling and use of
living modified organisms resulting from modern biotechnology that
have adverse effects on conservation and sustainable use of biological
diversity, taking also in to account risks to human. health, and
especially focusing on transboundary movements. 9
5) Second Conference of the Parties to the Convention on Biological I)iversity, DecisionII/5,
UNEP/CBD/COP/2/19 (Nov. 1995).
6 ) W Schweizer, "The Negotiation of the Cartagena Protocol on Biosafety", 6 Environment Law Journal
(2000). Three groups emerged during the negotiation: the Miami Group (which includes those countries
that have vested interest in trade in LMOs: Argentina, Australia, Canada, Chile, Uruguay and the
United States); the like-minded group (which includes the majority of developing countries and China)
and the European Union Countries.
7) As above. See also PE Hagen and JH Bellow, "The Cartagena Protocol on Biosafety: New rules for
international trade in LMOs", 12 Georgia International Law Review (2000).
8 ) Cartagena Protocol Article 27.
9 ) Cartagena Protocol Article 1.
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The Protocol came in to force on ll September 2003 and now membership stands
at110."
2.2　Scope of the Cartagena Protocol
The Cartagena Protocol applies to "the trans-boundary movement, transit,
handling and use of LMOs that may have adverse effects on the conservation and
sustainable use of biological diversity, taking in to account also risks to human
health.1-ll)
The general description of the scope of the Protocol could trigger different
questions and queries:
First, the scope of the Protocol is limited only to living modified organisms
which are defined by the Protocol itself as "any biological entity capable of
transferring or replicating genetic material, including sterile organisms, viruses
and viroids." This means that products of LMOs such as food, oil and clothing
are excluded from the scope of cover of the Protocol. Given the fact that LMO
products constitute most of the trade transactions, their exclusion from the
Proto∽1 could substantially reduce the possible dispute over trade in LMOs. Yet,
one may wonder why LMO products or commodities are excluded from the
Protocol. The issue has to be viewed in light of the objectives of the CBD in
general and that of the Protocol in particular. As stated above, the objective of the
CBD and the Protocol is the conservation and sustainable use of biodiversity and
to that extent, it could be said that LMO products are 'dead' and no longer
-'biological entity capable of transferring or replicating genetic material", and
consequently pose no treat to the conservation and sustainable use of biodiversity.
Their regulation is left for national legislation and other international agreements.
Second, Article 4, defining the scope of the Protocol states that the scope of
application of the Protocol is the transboundary movement of LMOs which may
have adverse effects on the conservation and sustainable use of biological diversity,
.-taking also in to account risks to human health". The plain reading of the phrase
''taking also in to account risks to human health" appears to be ambiguous. Why
? ? ? ? ????? ?
Information available at http://www.biodiv.org/world/parties.asp (accessed on 25 Nov. 2004).
Article 4.
Article 3 h).
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should a Protocol on conservation and sustainable use of biological diversity take
also in to account human health? What is the relationship between biodiversity
conservation and human health? The question may become even more puzzling in
view of the fact that Article 19(3) of the CBD which envisages the possibility of
negotiating the biosafety protocol makes no mention of risks to human health,
which may in turn, raises a question on the mandate of the Protocol.1
Nevertheless, Article 8(g) of the CBD obliges Members to regulate, manage or
control the risk associated with the use and release of LMOs resulting from
biotechnology which are likely to have adverse environmental impacts. Hence, the
possible challenge on the mandate of the Protocol as per Article 19(3) could
arguably be countered by the provisions of Article 8(g).
Different interpretations could be given to the phrase "taking also in to account
risks to human health." One may argue that the plain reading of Article 4 makes
human health risks an independent consideration under the Protocol in addition to
conservation and sustainable use of biodiversity. This argument could be defended
on the rule of interpretation of legal texts which states that no interpretation
should be made when the text is clear. Nevertheless, whether the phrase is clear
from the full reading of Article 4 is arguable, and even if it were clear, its
compatibility with the issue of conservation and sustainable use of biodiversity
would be questionable. Rather, the phrase "taking also in to account risks to
human health''should be considered in light of the scope and general objective of
the Protocol rather than on the basis of the mere phraseology under Article 4. It
is true that human health risks should be regulated, but the issue is whether such
risks should be regulated by an agreement dealing with conservation and
sustainable use of biodiversity. It does not seem that the Cartagena Protocol is the
appropriate regulatory platform for human health concerns as such. For example,
it would obviously be out of scope if the Protocol were intended to include human
health risks arising from consumption of LMO food. The Protocol is a biodiversity
protocol and not a food safety regulation. Human health issues arising from the
consumption of LMOs should be taken care of by other regulations at the national
13) Article 19(3) reads: "The Parties shall consider the need for and modalities of a protocol setting out
appropriate procedures, including, in particular, advance informed agreement, in the field of the safe
transfer, handling and use of any living modified organism resulting from biotechnology that may have
adverse effect on the conservation and sustainable use of biological diversity".
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and international levels.
Yet, one has to give a meaning to the phrase "taking in also in to account
human health risks.'- It could be argued, in light of the objective of the Protocol,
that human health risks should be considered only in relation to the environment,
i.e., human health risks which are incidental to or arise from the release of the
LMO to the environment and not from mere consumption of the LMO. There
could be situations where human health risks would result from direct biodiversity
impact. For example, there could be human health risks from direct contact with
LMOs such as allergenic reactions. Such kinds of risks are the result of direct
contact with the LMO released to the environment and not from consumption of
the products as such and they could still be covered under the Cartagena Protocol.
This interpretation seems to be more pertinent within the context of the objectives
and scope of the Protocol and the CBD as well.
LMO Pharmaceuticals are excluded from the application of the Protocol but only
under specific conditions.　Thus, to what extent Pharmaceuticals are excluded
from the Protocol is far from clear. In the first place, Pharmaceuticals containing
the organisms m living form appear to be uncommon; in most cases, they are
processed from the LMOs in which case they are automatically excluded from the
application of this Protocol by virtue of Article 4 which states that the Protocol
applies only to living modified organisms. This means that, Article 5 applies to
those pharmaceuticals which are released in to the environment in living forms, if
at all there are any such kinds of pharmaceuticals. Still, the exclusion of
pharmaceuticals under Article 5 applies only to those Pharmaceuticals which are
for humans and not addressed by other international agreements, and even then,
the exclusion is not mandatory since a party has always the right to subject all
living modified organisms to risk assessment prior to decision on imports under
Article 4.
14) Article 5 reads as follows: "Notwithstanding Article 4 and without prejudice to any right of a Party to
subject all living modified organisms to risk assessment prior to the making of decisions on imports, this
Protocol shall not apply to the transboundary movement of living modified organisms which are
pharmaceuticals for humans that are addressed by other relevant international agreements or
organizations.
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2.3　Key features of the Cartagena Protoco一
2.3.1 Advanced Informed Agreement (AIA) procedure
The AIA procedure seems to be at the heart of the Cartagena Protocol. How
does the AIA operate? First the party of export is obliged to notify or insure
notification in writing to the party of import about its intention to export a
particular LMO, before the first intentional import of any given type of LMO.ll
The party of import will then have　90　days to acknowledge receipt of the
notification, and advise that it intends to proceed with the Protocol-s decision
procedure, or according to its domestic regulatory framework.16'Before the party
of import makes a decision, a risk assessment must be carried out and the party
of import should inform the notifier that either it will have to wait for written
consent or it may proceed with the import with out a written consent.17'If the
exporter has to wait for written consent, the party of import should decide within
270 days on the fate of the application.18'The decision could be approval of the
import with or with out condition, prohibition of the import, requesting additional
information, or extending the deadline for response by a definite period.19'All
decisions are to be relayed on the Internet-Based Biosafety Clearing-House which
is established by the Protocol.20'some LMOs are not subject to the AIA procedure:
LMOs in transit to a third party21', LMOs destined for contained use22>, LMOs for
food and feed and processing23', and those declared safe by a meeting of the
Parties.24'It has to be noted that such LMOs should still be living (such as LMO
tomato, soya and cotton) so that they will fall be within the scope of the Protocol
since the processed foods and feed are already excluded from the application of the'''''''''''T
15) Article 8(1) Cartagena Protocol. The fact that the AIA procedure applies only for the first international
import LMO could be one concession given to those LMO exporting countries that have been arguing
that the procedure is cumbersome. The exporter's obligation under the AIA procedure is a one-time
obligation which need not be done for subsequent shipments of same LMO.
16) Article 9(1).
17)As above.
18) Article 10(3).
19)As above.
20)As above.
21) Article 6(1).
22) Article 6(2). The term "contained use" is defined in the Protocol as "any operation undertaken within
facility, installation or other physical structure, which involves living- modified organisms that are
controlled by specific measures that effectively limit their contact with, and their impact on, the external
environment".
23) Article 7(2).
24) Article 7(4).
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Protocol.
Yet, even if LMOs for food, feed and processing are not subject to the AIA
Procedure, they are still governed by a different set of rules under the Protocol
itself. So, what we see in the Protocol is that there are two distinct regimes, one
for LMOs to be directly released in to the environment and another for LMOs for
food, feed and processing.
For LMOs released into the environment in living form, the full AIA process
applies. As described above, the AIA places the burden on the exporting party or
on the actual exporter to notify the country of import, prior to any shipment, the
intention to export LMOs, and to receive their consent accordingly.2　For LMOs
used as food, feed or for processing, the burden lies on a Party to put in place a
domestic regime applicable to any use of LMOs, and inform the other Parties that
this regime will also be applicable to imported LMO products like food and feed.2'
While LMOs are governed by the provisions of Article 7-10 the LMO products like
food and feed are governed by those of Article ll. The difference is that the initial
responsibility of notification of exporting LMOs falls on the exporter while it is
the responsibility of the importing country to take prior action and notify to
other parties its domestic regulation for food, feed and processing products. Once
this latter responsibility is met, however, importing states can control imported
LMO for food, feed and processing just like LMOs themselves.　Hence, the
decision making procedure under Article ll, while allowing faster transaction still
gives much power to the importing country to control the import of LMOs for
food, feed or processing.
2二3.2　The precautionary principle
Precautionary principle has been a subject of immense controversy. It is
25) Article ll Cartagena Protocol.
26) Articles 7-10 Cartagena Protocol.
27) Article ll.
28) The fact that LMOs for food, feed and processing are excluded from the AIA procedure is a compromise
between the LMO exporting countries which insisted on the exclusion of such LMOs from the Protocol
as being not a threat to the environment and the majority of developing countries which argued for their
inclusion in to the full AIA procedure. The reason for the developing countries to take their position was
that even grains imported as foodstuff are often used as seeds by farmers, especially in a crisis situation
and hence could pose threat to biodiversity. See F Pyhthoud and U.P. Thomas, "The Cartagena Protocol
on Biosafety" in P.G. Le Prestre (ed.), Governing Global Biodiversity (2002)45.
29) For a detail discussions on the precautionary principle see, T. O'Riordan and J Cameron (eds.),
Interpreting the Precautbnary Principle (1994); P. Sands, Principles of International Environmental Law,
Vol I (1995) and D. Freestone and E. Hey (eds.), The precautionary Principle in mterna由onal Law,
Kluwer, (1996).
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basically an environmental law principle which is said to have been designed to
protect the environment from irreversible damage. Environmental damages could
be irreversible or even if they are reversible, they could be extremely expensive to
repair. Hence, prevention of environmental harm has always been considered the
best option. Environmental harm prevention is unarguable when there is clear
scientific evidence about the harm. However, the precautionary principle goes
further and provides that environmental harm prevention and protection measures
should not be deterred by lack of scientific evidence about the harm. The principle
was clearly articulated in the 1992 Rio Declaration, adopted by the United Nations
Conference on Environment and development (the Rio Declaration). Principle 15 of
the Rio Declaration provides:
In order to protect the environment, the precautionary approach shall
be widely applied by states according to their capabilities whether
there are threats or serious or irreversible damage, lack of full
scientific certaintシshall not be used as a reason for postponing cost
effective measures to prevent environmental degradation.
Thus, the precautionary principle enables states to take preventive measures in
the area of environment even in situations where there are scientific uncertainties
about the harm. The principle gives states some discretion to evaluate the
potential risks, even in cases of scientific uncertainty about the risk, weigh the
potential harm and take the appropriate measure. The issue is not whether the
risk will certainly materialize or not, it is rather the impact of the risk in case it
materializes. Given the fact that environmental harm is irreversible and
consequences are immense, the principle sounds convincing, at least in theory. The
problem is in the practical applicability of the principle. There are opinions against
this principle which, inter alia, include that the principle is against.science and
that it could be taken as disguised protectionism in trade.壬n the case of LMOs,
the possible explanation of the precautionary principle is the absence of scientific
certainty and consensus as to their potential risks on the environment and human
health.
A number of provisions in the Cartagena Protocol incorporate or indicate the
precautionary principle. It is in fact natural for the Protocol to incorporate the
precautionary principle since, it is also reflected in its parent legislation, the
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CBD.30) The preamble and Article 1 of the Protocol simply refer to the
precautionary principle as enshrined in Principle 15　0f the Rio Declaration.
Nonetheless, the precautionary principle as stated in the preamble is just a
declaration of intention of the Parties whereas its mention under Article 1 is
general which is stated in the context of the objective of the Protocol. This means
that, the precautionary principle as incorporated in the preamble and Article 1 is
not operational and enforceable. Yet, the Protocol also includes provisions on the
precautionary principle in its operational part as well. For example, Articles 10(6)
and ll(8) clearly state that lack of scientific certainty due to insufficient relevant
scientific information and knowledge regarding the extent of potential adverse
effects of LMOs shall not prevent a party of import from taking a decision, as
appropriate, with regard to the import of the LMO in question. The two articles
clearly allow the party of import to take measures on LMOs on the basis of the
precautionary principle.3
2.3.3　Risk assessment and risk management
The Protocol obliges parties to carry out risk assessment before making a
decision on the request to export LMOs. The risk assessment should be carried
out in a scientifically sound manner, and in accordance with Annex III of the
Protocol, taking into account recognized risk assessment techniques.*
The Protocol also puts. obligation on the Parties on risk management.
Accordingly, parties should establish and maintain appropriate mechanisms,
measures and strategies to regulate, manage and control risks identified m the
risk assessment provisions of the Protocol. In relation to this each Party should
endeavor to ensure that any LMO, whether imported or locally developed, has
undergone an appropriate period of observation that is commensurate with its life-
cycle or generation time before it is put to its intended use. On the other hand,
the Protocol states that such risk management measures should be imposed only
to the extent necessary to prevent adverse effects of LMOs on the conservation
30) The precautionary principle is reflected in the preamble of the CBD.
31) It s to be noted that the Articles 10(6) and ll(8), and any other article of the Protocol, for that matter,
except the inoperable preambular provision and Article l.never use the phrase 'precautionary principle.
32) Articles 10(1) and 15 Cartagena Protocol.
33) Article 15.1 Cartagena Protocol.
34) Article 16(1).
35) Article 16(4).
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and sustainable use of biological diversity, taking also into account risks to human
health.3'
3. WTO Agreements and LMOs
Trade-related measures related to LMOs could fall under three WTO
agreements-the Agreement on the Application of Sanitary and Phytosanitary
Measures (SPS Agreement), the Agreement on Technical Barriers to Trade (TBT)
and the General Agreement on Tariffs and Trade (GATT)∴
3.1 The SPS Agreement
The SPS Agreement regulates sanitary and phytosanitary (SPS) measures which
Members may take in order to protect the life and health of human beings,
animals and plants from pests and diseases, disease- causing organisms, toxins,
additives and contaminants.3" The Agreement defines SPS measures as those
measures applied to protect animal or plant life or health within the territory of
the Member from risks arising from the entry, establishment or spread of pests,
diseases, disease-carrying organisms or disease-causing organisms; to protect
human or animal life or health within the territory of the member from risks
arising from additives contaminants, toxins or disease-causing organisms in foods,
beverages or feedstuffs; and to protect human life or health within the territory
of the member from risks arising from disease carried by animals, plants or
products thereof or from the entry, establishment or spread of pets.31
The SPS measures are to be taken on the basis of scientific principles and should
be supported by scientific evidence.39'such measures should not discriminate among
members and should not be used as a disguised barrier to trade.40'Members are
also required to base their SPS measures on international standards, guidelines or
recommendations where they exist.41'To that end, the Agreement refers to three-.・・.I-.・.・.・.・.-.・.・.・.・.・.-.・.・.・.・.・.+
36) Article 16(2).
37) See Article 2 0f the SPS agreement on the general rights and obligations of Members.
38) Annex 1 SPS Agreement.
39) Article 2.2 SPS Agreement.
40) Article 2.3.
41) Article3.
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international organizations as standard-setting institutions:　the Codex
Ahmentarms Commission in relation to food safety standards; the international
Office of Epizootics in relation to animal health and zoonoses; and the Secretariat
of the International Plant Protection Convention in relation to plant health.4
However, Members are also allowed under certain circumstances to adopt higher
standards than those set by the international organizations.　SPS measures
should be taken after a risk assessment which should take in to account, inter alia
the available scientific evidence, relevant processes and production methods,
relevant inspection, sampling and testing methods.4'
Once the risk is assessed, the measures to be taken are generally left for the
Member, but the latter is required to minimize the negative effects of the
measures on trade and must ensure that the measure are not more trade-
restrictive than required to achieve the desired level of SPS protection.41
3.2　The Agreement on Technical Barrier to Trade (the TBT Agreement)
The TBT Agreement regulates measures affecting trade which are technical and
industrial standards, and that do not fall under the SPS Agreement, i.e. measures
which are not sanitary or phytosanitary. The TBT Agreement allows Members
to formulate national regulations, which should not be more trade-restrictive than
necessary, to fulfill a legitimate objective. Such legitimate objectives are, inter
αZiα: national security requirements; the prevention of deceptive practices and
protection of human health or safety, animal or plant life or health, or the
environment.
While recognizing the right of Members to adopt the standards they consider
appropriate, the TBT Agreement tries to ensure that the regulations, standards,
testing and certification procedures (which vary from country to country) do not
create unnecessary obstacles.　Accordingly, Members should ensure that their
42)Annex A.
43) Proゼided they are based on scientific justification or are made in accordance with the other requirements
of Article 3.3, the SPS Agreement.
44) Article 5.2.
45) Article 5.4 and 5.6.
46) See Articles 2.2 and 1.5 0f the TBT Agreement.
47) Article 2 0f the TBT Agreement.
48) Article 2.2 the TBT Agreement.
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technical regulations do not discriminate products from different countries (MFN
principle) and between domestic and imported products (national treatment).49'TBT
measures should not also create unnecessary barriers to trade and hence they
should not be more trade-restrictive than necessary for a legitimate objective. In
assessing the risk, Members should consider the available scientific and technical
information, related processing technology or intended end-uses of products.5" The
TBT Agreement also requires Members to apply their technical regulations based
on available and relevant standards formulated by an international body unless
those standards would be ineffective or inappropriate to fulfill the legitimate
objective the parties want to pursued
3.3　GATT
The core principles under the GATT are the Most Favored Nation (MFN) and
the National Treatment. GATT obliges Members not to discriminate between -'like
products imported from different Members but give them equal treatment.53)
Similarly, Members are required not to discriminate between domestic and
imported products. The two principles are meant to prohibit discrimination in
international trade so that the trade will be 'free' and　-fairl. But the GATT
prohibits discrimination between "like products-　and hence determination of what
products are like is fundamental for the application of the core principles of the
GATT. Even if the GATT does not clearly define what products are to be
considered like, the jurisprudence of the WTO dispute settlement body, which has
addressed the issue in several cases, provides some clue. An often-quoted case that
provides a general guideline on the issue is the European Communities Measures
Affecting Asbestos and Asbestos-Containing Products where the Appellate Body
stated that whether two products are alike should be determined on a case-by-case
basis and provided some criteria to help determine whether products are like: the
physical properties of the products, the extent to which the products re capable of
serving the same or similar end-uses, the extent to which consumers perceive and
49) Article 2 TBT Agreement.
50) Article 2.2.
51)As above.
52) Article 2.4.
53) Article I GATT.
54) Article III.
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treat the product as alternative means of performing particular functions in order
to satisfy a particular want or demand, and the international classification of
products for tariff purposes.55'These are possible considerations and it seems that
the list is not an exhaustive and the requirements are not cumulative. The issue
should still be considered on a case-by-case basis as determined by the Appellate
Body.
GATT provides exceptional situations where Members could derogate from the
application of the MFN and the national treatment principles. According to Article
XX, Members could take necessary measures to protect human, animal or pant life
or health or for the conservation of exhaustible natural resources with out the
need to be bound by the MFN and national treatment principles. But such
measures should not be applied as means of arbitrary or unjustifiable
discrimination between countries or as a disguised restriction on international
trade.51
3.4　Determining the WTO agreement applicable to LMOs
Authorities differ on the issue as to which WTO agreement applies to measures
taken on LMOs under the Cartagena Protocol. For example Co fs argues that the
SPS Agreement is the pertinent Agreement that should be applicable, whereas
Torres58'alleges that TBT or the GATT is applicable in relation to trade on LMOs.
The issue should be determined in light of the objective and purpose of the
measures taken in accordance with the Cartagena Protocol. As discussed earlier,
measures taken under the Protocol are related to biodiversity conservation and its
sustainable use, taking also in to account human health risks. On the other hand,
SPS measures are to be taken to protect the life or health of human beings,
animals or plants. Could it be said that the protection of human, animal or plant
life or health under the SPS Agreement is directly related to conservation of
biological diversity? Some commentators answer the question in the negative:
55) WTO Appellate Body Report On European Communities Measures Affecting Asbestos and Asbestos-
containing Products, WT/DS135/AB/R ( March 12, 2001).
56) Article XX GATT.
57) TA Cors, "Biosafety and international trade: conflict or convergence", 2 Journal of Biotechnology (2000).
58) OR Torres, The Biosafety Protocol and the WTO (2002).
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Biodiversity is a distinct environmental concern that transcends
typical sanitary and phytosanitary concerns. According to the
definition of biodiversity in the CBD, this term focuses on the
diversity among genes, the diversity among and within species, and
the diversity among and within ecosystems. This last concept of
ecosystem biodiversity is not solely centered around the extinction of
one genetically unique organism, but around 'the effects that
extinction of an organism can have on the remaining environment.
Thus the question of whether a ban undertaken by a party to the
Protocol with the objective of conserving biodiversity should be
considered as SPS measure must be addressed seriously.5'
The argument seems to make a kind of not-easy-to-comprehend distinction
between biodiversity and its constituent parts and suggests that the protection of
the latter may not necessarily be protection of the former. Yet, it is the animals
and plants that constitute the biodiversity and to that extent protecting those
living things has a direct impact on the conservation of biodiversity. In other
words, protecting plant and animal life/ health by SPS measures is at the same
time protecting biodiversity. Treating biodiversity as something independently
existing from its component parts appears to be at best unwarranted abstraction
of the issue. Hence, one could counteJ the above argument and say that SPS
measures are directly relevant to biodiversity conservation and the SPS Agreement
could be the appropriate agreement applicable to measures taken in relation to
LMOs under the Protocol. Concerning human health risks, their inclusion in the
SPS Agreement is clear in cases where such risks are taken as an independent
consideration under the Protocol different from biodiversity, and the above
argument would apply to them when their inclusion in the Protocol is considered
within the broader biodiversity conservation objective.
Once it is established that measures taken under the Protocol could be taken as
SPS measures, then the possibility of applicability of the TBT Agreement will
automatically be ruled out by virtue of Article 1.5　0f the Agreement which
59) Torres (above) 18.
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specifically states that measures covered by SPS Agreement are excluded from the
TBT Agreement. As stated earlier, the GATT also allows parties to take measures
which are considered legitimate with a view to protect human, animal or plant life
or health or in relation to conservation of exhaustible natural measures (Article
XX GATT). It seems that under certain circumstances measures taken against
LMOs in accordance with the Protocol could fall under Article XX of the GATT.
In such cases, the lex specialis rule could apply and the SPS Agreement, being a
special Agreement within the GATT, prevails over the general GATT rules.
4. WTO rules and the Cartagena Protocol in conflict or harmony?
In order to determine whether or not the WTO rules and the Cartagena Protocol
are m conflict, it must first be established that there is a common area of
operation for the two agreements. In the absence of a common area of application,
a conflict would not arise and this makes any discussion on interpretation
superfluous.
The Cartagena Protocol is basically an environmental agreement where as WTO
is a trade agreement. Yet, this does not automatically mean that the two
agreements have no common area of application. Though with the objective of
conservation and sustainable use of biodiversity, the Protocol deals with
international transactions involving LMOs- an area of international trade. Hence,
it is clear that the two agreements have a common area of operation/application.
Once it is established that there is a common area of application between the two
agreements, the next issue to be analyzed is where there could be a potential
conflict between the two agreements.
As discussed above, SPS measures should be taken based on scientific principles
and be supported by scientific evidence. A risk assessment has to first be carried
out before SPS measures are taken. According to Annex A of the SPS Agreement,
risk assessment is to be carried out with a view to:
1. evaluate the likelihood of entry, establishment, or spread of a pest
or disease within the territory of an importing member according
to the sanitary and phytosanitary measures which might be
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applied, and of the associated potential biological and economic
consequences; or
2. evaluate the potential for adverse effects on human or animal
health arising from the presence of additives, contaminates, toxins
or disease-causing organism m food, feedstuffs and beverages.
Similarly, the decision on importation of LMOs under the Protocol should be
made on the basis of a risk assessment carried out in a scientifically sound
manner.　Annex III of the Protocol also provides the detail risk assessment
procedure and affirms that the risk assessment sho山d be made in a scientifically
sound and transparent manner. The objective of the risk assessment as stated in
Annex III of the Protocol is to "identify and evaluate the potential adverse effects
of living modified organisms on the conservation and sustainable use of biological
diversity in the likely potential receiving environment, taking also in to account
risks to human health". As sated earlier, protection of plant and animal life and
health is directly related to protection of the biodiversity or the environment since
the plants and animals are the components of the biodiversity or environment.
Thus, in principle there appears no conflict between the SPS agreement and the
Protocol on the objective of the risk assessment and the way it has to be
undertaken.
Still, the SPS Agreement requires that the SPS measures which have to be taken
after a risk assessment should take in to account the objective of minimizing
negative effects on trade and should not be more trade-restrictive than required to
achieve the intended purpose of SPS protection. Similarly, the Protocol requires
that the measure to be applied on LMOs should be based on a risk assessment and
should be applied to the extent necessary to prevent adverse effects on biological
diversity.　This suggests that the Party to the Protocol should apply less
restrictive measures when they are available and are sufficient to achieve the
purpose sought to be achieved. Hence, in this regard, too, there appears no
apparent conflict between the two agreements.
60) Articles 10(1) and 15(1), Cartagena Protocol.
61) Article 5.4 and 5.6 SPS Agreement.
62) Article 16(2) Cartagena Protocol.
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While the principle under the Protocol is that measure against LMOs should be
taken on the basis of a scientifically sound risk assessment, it is also stated that
lack of scientific evidence should not deter a party from taking measures as
appropriate (the precautionary principle). Article 10(6) reads:
Lack of scientific certainty due to insufficient relevant scientific
information and knowledge regarding the extent of the蝣potential
adverse effects of a living modified organism on the conservation and
sustainable use of biological diversity in the party of import… shall
not prevent a party from taking a decision as appropriate‥‥
The precautionary principle is in the same way incorporated under Article ll(8)
of the Protocol in relation to LMOs for direct food, feed or processing. Further
more, the precautionary principle is mentioned in Annex III of the Protocol as one
important principle of risk assessment. Indeed, the fact that precautionary
principle is mentioned in the preamble and article l(objective) shows the weight the
parties have given to the principle and suggests that it is a fundamental principle
under the Protocol.
Precautionary principle is also recognized under the SPS Agreement, albeit as an
exception. Article 5.7 states:
In cases where relevant scientific evidence is insufficient, a Member
may provisionally adopt sanitary and phytosanitary measures on the
basis of available pertinent information, including that from relevant
international organizations as well as from sanitary and
phytosanitary measures applied by other members. In such
circumstances, Members shall seek to obtain the additional
information necessary for a more objective assessment of risk and
review the sanitary or phytosanitary measures accordingly within a
reasonable period of time.
The WTO Appellate Body also affirmed that the precautionary principle is
recognized under Article 5.7 0f the SPS Agreement but it also emphasized that the
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principle as stated under article 5.7 cannot override the provisions of article 5.1
and 5.2. Article 5.1 and 5.2 state that SPS measures should be taken on the basis
of a risk assessment carried out in accordance with scientific principles and
scientific evidences. In this context the Appellate Body seems to recognize that a
member country may invoke the precautionary principle when determining its level
of protection, as long as long as a risk has been identified pursuant to article 5.1
and 5.2.64　Thus, what we see is that the precautionary principle as stated under
article 5.7 0f the SPS Agreement and as interpreted by the WTO Appellate Body
does not apply to risk assessment but only to determine the level of SPS measures
once the risk is identified pursuant to a scientific based risk assessment. This
appears to be one possible area of conflict between the SPS Agreement and the
Cartagena Protocol. As far as the latter is concerned, precautionary principle is
applicable not only merely to determine the extent of measures to be taken against
LMOs but also as one basic principle of risk assessment. The Protocol clearly
states that　-'Lack of scientific kndwledge or scientific consensus should not
necessarily be interpreted as indicating a particular level of risk, an absence of
risk, or an acceptable risk". It is fairly clear that the precautionary principle in
the Protocol applies in the process of risk assessment whereas it is applied in the
SPS Agreement only to determine the measures to be taken after a risk has been
identified. Hence, there appears an apparent conflict in the two agreements on the
application of the precautionary principle.
Further, SPS measures could only be taken provisionally in accordance with the
precautionary principle, and a member that has taken such measures is obliged to
seek to obtain additional information necessary for a more objective assessment of
the risk and review the measures accordingly within a reasonable period of time.
While review of decisions is a possibility under Article 12 0f the Protocol, such a
review is not mandatory for the party that took the measures and in any event
such a Party is not bound to change the decision based on the new scientific
information.
63) WTO Appellate Body Report on European Community Measures Concerning Meat and Meat Products,
WT/DS26/AB/R (Jan.16, 1998).
64) Torres (note 55 above) 15.
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0nce it is shown that there could be a conflict between the SPS Agreement and
the Cartagena Protocol, the next issue is as to how to resolve these potential
conflicts.
On the relationship between trade and environment on the one hand and the
Protocol and other agreements on the other, the pertinent part of the preamble of
the Protocol states as follows:
Recognizing that trade and environment agreements should be
mutually supportive with a view to achieving sustainable development,
Emphasizing that this Protocol shall not be interpreted as implying
a change in the rights and obligations of a party under any existing
international agreements,
Understanding that the above recital is not intended to subordinate
this Protocol to other international agreements…
The preambular paragraphs, confusing as they are, seem to create more problem
than they solve on the relationship between the Protocol and other agreements like
the WTO. While the second paragraph states that the Protocol should not bring
about a change in other obligations of parties in other international agreements
including the WTO, the third paragraph asserts that the Protocol is not
subordinate to any international agreement, including WTO. Read together, the
two preambular paragraphs seem to suggest that there should be no hierarchy
between the Protocol and other international agreements including WTO. This
makes the matter more complicated since in case of conflict between the Protocol
and the WTO Agreements, one should necessarily prevail over the other, provided,
of course that there will be no possibility of applying the two agreements in a
harmonious manner as stated in the first paragraph of the preamble.
Despite the above complication, the main issue remains as to how to resolve
possible conflicts between the Protocol and the WTO Agreements. For example, if
a country bans a particular LMO on the basis of the Protocol and such measure
is蝣challenged as contrary to WTO rules, how should the issue be resolved? This
issue should be addressed in two different scenarios: when a dispute arises in the
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WTO between a party and non-party to the Protocol, and between parties to the
Protocol and the WTO.
4.1 Dispute in the WTO between a party and non-party to the Cartagena Protoco一
Article 24(1) of the Protocol provides that "Transboundary movements of living
modified organisms between parties and non-parties should be consistent with the
objective of this Protocol". The Article further allows parties to enter in to
bilateral, regional and multilateral agreements and arrangements with non-parties
regarding such transboundary movements. If such bilateral, regional or
multilateral agreements exist, then the possibility of conflict being addressed by
the WTO will be unlikely. Yet, in the absence of such agreements or
arrangements, the party to the Protocol would require the non-party to comply
with the procedures in the Protocol for exporting LMOs in the territory of the
party, or the party to the Protocol could ban importation of a particular LMO
pursuant to the provisions of the Protocol,早nd this could trigger complaint under
WTO rules.
In such circumstances, the Vienna Convention on the Law of Treaties65'could be
of help. According to the Vienna Convention, when there is a dispute concerning
two treaties on the same subject matter between a state that is a party to both
and a state that is a party to one, the treaty to which both states are parties
governs their mutual rights and obligations. In cases concerning measures on
LMOs, the SPS Agreement will determine a dispute where both states are
members of the WTO but only one is a party to the Cartagena Protocol. In
relation to the precautionary principle, the implication of this interpretation is
that.the principle will be applicable in relation to determination of the level of
measure to be taken and not for risk assessment as is enshrined in the SPS
Agreement and interpreted by the WTO Appellate Body.
4.2　Con川ct between parties to both agreements
In cases where a dispute arises between members of both agreements, two
principles could apply, at least. The first is the one provided in the Vienna
65) Vienna Convention on the Law of Treaties, May 23, 1969, UN Doc.A/Conf.39/27 (1969).
66) Article 30(4)(b), Vienna Convention on the Law Of Treaties.
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Convention and which states that the later treaty in time will prevail over the
former. The SPS Agreement came to force in 1994 while the Cartagena protocol
m 2003, which means that the latter will prevail over the former m relation to
trade in LMOs.
The other possibility is the lex speciahs principle according to which when two
agreements deal with the same issue, the more specific or special agreement will
prevail (lex specialis derogate generalis). This principle, hence, calls for
determination of which agreement is more specific than the other, m our case, the
SPS or the Cartagena Protocol. In relation to LMOs, it appears that the
Cartagena Protocol is the one that specifically deal with them and hence it can be
argued that the Protocol should prevail over the SPS Agreement.
5. Conclusion
As the commercialization and transboundary movement of LMOs increase the
need for regulation appears to be crucial. The Cartagena Protocol is the result of
the need for harmonization of regulations on LMOs. It is an important
development at the international level concerning the safe use of LMOs. The
Protocol's relation with WTO rules has yet to be settled but there are several cases
where the provisions of the Protocol could be used without violating the WTO
rules. Whether the WTO dispute settlement body will recognize the Protocol as a
standard m relation to trade on LMOs or will discard it as inconsistent with the
WTO agreements is yet to be seen.
67) Article 30(4)(a) and article 59.
